Collegium Pharma (COLL) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Janney Capital Starts Collegium Pharmaceutical (COLL) at Buy
March 15, 2016 6:49 AM EDTJanney Capital initiated coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.
Shares of Collegium Pharmaceutical closed at $17.83 yesterday.
... More